IDEAYA Biosciences, Inc. (IDYA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

IDEAYA Biosciences said it is nearing completion of its NDA submission for darovasertib in metastatic uveal melanoma, with the first three modules already submitted under the FDA's Real-Time Oncology Review process and the final module expected shortly. Management highlighted darovasertib as its late-stage lead asset and indicated that several pipeline readouts are expected over the coming months. The advancing regulatory filing provides a positive catalyst for IDYA, although approval timing and clinical-readout outcomes remain key risks.

Analysis

IDYA is transitioning from a platform-valued oncology developer to a commercial-stage, single-asset-risk story. The key rerating mechanism is not merely regulatory clearance: investors will need evidence that darovasertib can address patients outside Immunocore's (IMCR) HLA-A*02:01-restricted KIMMTRAK population and achieve durable uptake in a concentrated specialist market. If so, IDYA's valuation should begin to reflect revenue durability and strategic scarcity; if not, a successful approval could still produce a sell-the-news outcome as commercialization spend and launch uncertainty replace development optionality.

Near term, the stock is likely governed by regulatory submission/acceptance mechanics and labeling expectations rather than fundamentals. The most material downside is that safety, durability, or combination-regimen language constrains use to a narrower salvage setting, which would reduce peak-sales assumptions and make IDYA more directly dependent on future pipeline readouts. A second-order beneficiary of a differentiated IDYA label would be specialty oncology distributors and selected trial-site networks, while IMCR faces incremental competitive risk only if IDYA demonstrates credible activity in HLA-A*02:01-positive patients rather than simply expanding treatment access in the unaddressed population.

Consensus may be underweighting execution risk after approval: metastatic uveal melanoma is commercially attractive because prescribers are concentrated, but small patient numbers make quarterly revenue highly sensitive to diagnosis rates, biomarker testing, treatment sequencing, and inventory dynamics. Conversely, the market may be over-discounting IDYA's strategic value if approval validates its precision-oncology development and regulatory capabilities, increasing the probability of partnership or M&A interest from larger oncology franchises. There is no read-through to Citi (C) beyond routine conference sponsorship.

Key Decisions for Investors

• Maintain IDYA as a modest event-driven long only after confirming FDA filing acceptance and review designation; add on acceptance-related weakness rather than chase pre-event momentum. The upside case is a commercial-stage rerating plus strategic-value premium over the following 6-18 months, while the primary risk is label narrowing or review delay.
• Use a defined-risk structure around the regulatory decision: long IDYA shares paired with protective puts dated beyond the expected action window, or a call spread rather than outright short-dated calls. This preserves exposure to approval/M&A upside while limiting the binary drawdown associated with a complete-response letter or unfavorable labeling.
• Monitor IMCR versus IDYA as a competitive alert, not a current pair trade. Consider long IDYA/short IMCR only if IDYA's final label and launch evidence support use in biomarker-overlapping patients; absent that evidence, the products are more likely complementary than substitutive.
• Set thesis-falsification triggers: reduce IDYA if the review timeline extends materially, if labeling restricts use below current commercial expectations, or if initial launch metrics show weak specialist adoption and management lowers peak-sales or launch guidance within the first two reported quarters.